APOM and hepatocellular carcinoma: For instance, recent studies using the CRISPR system have provided evident proof that Wnt3a (Sai et al., 2019) and Apolipoprotein M (Yu et al., 2019a) can be rational targets for hepatocellular carcinoma (HCC) therapy.